Genmab A/S, a specialist in creating and developing fully human, monoclonal antibodies for treating serious diseases, is nearing its goal of getting its first antibody product onto the market since the company was founded in February 1999.
Genmab A/S, a specialist in creating and developing fully human, monoclonal antibodies for treating serious diseases, is nearing its goal of getting its first antibody product onto the market since the company was founded in February 1999.